7 Matching Annotations
  1. Nov 2025
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T Cell and Immunotherapy Responses in Prostate Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12471896/
  3. Jul 2024
  4. www.sciencedirect.com www.sciencedirect.com
    Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2211124724008611
  5. May 2024
  6. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    1-s2.0-S2589004224013270-main-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11342199/
  7. Feb 2024
  8. www.sciencedirect.com www.sciencedirect.com
    SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0092867424000102
  9. Oct 2023
  10. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
    2
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC10591052/
  11. Apr 2023
  12. aacrjournals.org aacrjournals.org
    IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/cancerrescommun/article/3/4/576/725855/IOA-244-is-a-Non-ATP-competitive-Highly-Selective